Eleven Connecticut residents have been diagnosed with mpox this year, an increase from four in 2023, Ed Stannard of the Hartford Courant reports. The patients are between the ages of 20 and 50 and most have not been hospitalized, according to the report. Shares of Siga Technologies, whose lead product is an antiviral drug for the treatment of human smallpox disease, are up are up 5.3% to $8.15 in morning trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIGA:
- WHO, scientists says new mpox strian must be addressed urgently, Reuters says
- Siga Technologies to expand access to Tpoxx to ASEAN member states
- SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States
- Calidi enters collaboration with Siga Technologies to support RTNova development
- Biotech Alert: Searches spiking for these stocks today